Ulcerative Colitis Partnering 2009-2014

  • August 2014
  • -
  • Currentpartnering
  • -
  • 100 pages

The Ulcerative Colitis Partnering 2009-2014 report provides understanding and access to the ulcerative colitis partnering deals and agreements entered into by the worlds leading healthcare companies.

•Trends in ulcerative colitis partnering deals
•Top ulcerative colitis deals by value
•Deals listed by company A-Z, industry sector, stage of development, technology type

The Ulcerative Colitis Partnering 2009-2014 provides understanding and access to the ulcerative colitis partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of ulcerative colitis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors ulcerative colitis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 50 links to online copies of actual ulcerative colitis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of ulcerative colitis partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in ulcerative colitis partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading ulcerative colitis deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of ulcerative colitispartnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of ulcerative colitis technologies and products.

Report scope

Ulcerative Colitis Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to ulcerative colitis trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

•Trends in ulcerative colitis dealmaking in the biopharma industry since 2009
•Access to summary headline, upfront, milestone and royalty data
•Access to over 50 ulcerative colitis contract documents
•The leading ulcerative colitis deals by value since 2009

In Ulcerative Colitis Partnering 2009-2014, the available deals are listed by:

•Headline value
•Upfront payment value
•Royalty rate value
•Company A-Z
•Industry sector
•Stage of development at signing
•Deal component type
•Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table Of Contents

Executive Summary



Chapter 1 - Introduction



Chapter 2 - Trends in ulcerative colitis partnering


•2.1. Introduction
•2.2. Ulcerative colitis partnering over the years
•2.3. Bigpharma ulcerative colitis dealmaking activity
•2.4. Ulcerative colitis partnering by deal type
•2.5. Ulcerative colitis partnering industry sector
•2.6. Ulcerative colitis partnering by stage of development
•2.7. Ulcerative colitis partnering by technology type
•2.8. Disclosed financial deal terms for ulcerative colitis partnering
•2.8.1 Ulcerative colitis headline values
•2.8.2 Ulcerative colitis upfront payments
•2.8.3 Ulcerative colitis milestone payments
•2.8.4 Ulcerative colitis royalty rates



Chapter 3 - Leading ulcerative colitis deals


•3.1. Introduction
•3.2. Top ulcerative colitis deals by value
•3.3. Top ulcerative colitis deals involving bigpharma



Chapter 4 - Dealmaking directory


•4.1. Introduction
•4.2. Company A-Z
•4.3. By deal type
•Asset purchase
•Bigpharma outlicensing
•Co-development
•Collaborative RandD
•Co-market
•Contract service
•Co-promotion
•CRADA
•Cross-licensing
•Development
•Distribution
•Equity purchase
•Evaluation
•Grant
•Joint venture
•Licensing
•Manufacturing
•Marketing
•Option
•Promotion
•Research
•Settlement
•Spin out
•Sub-license
•Supply
•Termination
•4.4. By industry sector
•Academic
•Bigpharma
•Biotech
•Drug delivery
•Medical device
•Diagnostic
•Generic pharma
•Government
•Non-profit
•Pharmaceutical
•Research tools
•Services
•Specialty pharma
•4.5. By stage of development
•Discovery
•Pre-clinical
•Phase I
•Phase II
•Phase III
•Registration
•Marketed
•4.6. By technology type
•Analysis
•Animal models
•Assays
•Bioinformatics
•Biological compounds
•Biomarkers
•Biomaterials
•Cell culture
•Cell therapy
•Clinical testing
•Diagnostic - companion
•Devices
•Diagnostics
•Discovery tools
•DNA probes
•Drug delivery
•Enabling technology
•Epigenetics
•Equipment
•Facilities
•Gene therapy
•Genomics
•Imaging
•Industrial chemicals
•In vitro models
•Monoclonal antibodies
•Nanotechnology
•Oligonucleotide
•Peptides
•Personalised medicine
•Processes
•Proteomics
•Radio/Chemo-therapy
•Recombinant DNA
•Research services
•Research supplies
•RNA therapeutics
•Screening
•Small molecules
•Stem cells
•Vaccines



Chapter 5 - Partnering resource center


•5.1. Online partnering
•5.2. Partnering events
•5.3. Further reading on dealmaking



Appendices


•Appendix 1 - Deal type definitions



About Wildwood Ventures


•Current Partnering
•Current Agreements
•Recent titles from CurrentPartnering
•Order Form - Reports




Table of figures


•Figure 1: ulcerative colitis partnering since 2009
•Figure 2: Bigpharma - top 50 - ulcerative colitis deals 2009 to 2011
•Figure 3: Bigpharma ulcerative colitis deal frequency - 2009 to 2011
•Figure 4: Ulcerative colitis partnering by deal type since 2009
•Figure 5: Ulcerative colitis partnering by industry sector since 2009
•Figure 6: Ulcerative colitis partnering by stage of development since 2009
•Figure 7: Ulcerative colitis partnering by technology type since 2009
•Figure 8: Ulcerative colitis deals with a headline value
•Figure 9: Ulcerative colitis deals with upfront payment values
•Figure 10: Ulcerative colitis deals with milestone payments
•Figure 11: Ulcerative colitis deals with royalty rates, %
•Figure 12: Top ulcerative colitis deals by value since 2009
•Figure 13: Top ulcerative colitis deals signed by bigpharma value since 2009
•Figure 14: Online partnering resources
•Figure 15: Forthcoming partnering events
•Figure 16: Deal type definitions

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...

Sleep Aids : Technologies and Global Markets

Sleep Aids : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

Research on the working of the human brain in relation to sleep is a fairly new area, with many new and novel theories. The discovery of new mechanisms and chemicals in the brain has provided expanding ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.